Distinctive Behaviors of Druggable Proteins in Cellular Networks

PLoS Computational Biology

Volumn 11, Issue 12, 2015, Pages

  Mitsopoulos, Costas ^a   Schierz, Amanda C ^a,b   Workman, Paul ^a   Al Lazikani, Bissan ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b DataRobot Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES; MOBILE TELECOMMUNICATION SYSTEMS; WIRELESS NETWORKS;

CANCER DRUG; CELLULAR NETWORK; COMPUTATIONAL ANALYSIS; DRUG DISCOVERY; DRUG TARGETS; INTERACTION ENVIRONMENT; INTERACTOME; NETWORK ENVIRONMENTS; NETWORK PARAMETERS; TARGETS SELECTION;

PROTEINS;

PROTEIN; ANTINEOPLASTIC AGENT; TUMOR PROTEIN;

ACCURACY; AMINO ACID SEQUENCE; ARTICLE; CONTROLLED STUDY; DRUG TARGETING; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; PREDICTION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; ALGORITHM; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; COMPUTER ASSISTED DRUG THERAPY; COMPUTER SIMULATION; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; DRUG EFFECTS; HUMAN; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PROCEDURES; PROTEIN ANALYSIS; SIGNAL TRANSDUCTION;

ALGORITHMS; ANTINEOPLASTIC AGENTS; COMPUTER SIMULATION; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; DRUG THERAPY, COMPUTER-ASSISTED; HUMANS; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; NEOPLASMS; PROTEIN INTERACTION MAPPING; SIGNAL TRANSDUCTION;

EID: 84953238959     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1004597     Document Type: Article

References (64)

1. Workman P, Al-Lazikani B, (2013) Drugging cancer genomes. Nat Rev Drug Discov 12: 889–890. doi: 10.1038/nrd4184 24287764
2. Hopkins A, Groom C, (2002) The druggable genome. Nat Rev Drug Discov 1(9): 727–730. 12209152
3. Hajduk PJ, Huth JR, Fesik SW, (2005) Druggability indices for protein targets derived from NMR-based screening data. J Med Chem 48: 2518–2525. 15801841
4. Al-Lazikani B, Gaulton A, Paolini GV, Lanfear J, Overington JP, et al. (2007) The Holy Grail: Molecular Function—The Molecular Basis of Predicting Druggability. Bioinformatics: From Genomes to Therapies. Wiley-VCH, Vol. 3.
5. Keller TH, Pichota A, Yin Z, (2006) A practical view of 'druggability'. Curr Opin Chem Biol 10(4): 357–361. 16814592
6. Bakheet TM DA, (2009) Properties and identification of human protein drug targets. Bioinformatics 25(4): 451–457. doi: 10.1093/bioinformatics/btp002 19164304
7. Agüero F, Al-Lazikani B, Aslett MA, Berriman M, Buckner FS, et al. (2008) Genomic-scale prioritization of drug targets: the TDR Targets database. Nat Rev Drug Discov 7: 900–907. doi: 10.1038/nrd2684 18927591
8. Bickerton GR, Paolini GV, Besnard J, Muresan S, Hopkins AL, (2012) Quantifying the chemical beauty of drugs. Nat Chem 4: 90–98. doi: 10.1038/nchem.1243 22270643
9. Hopkins AL, (2008) Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 4: 682–690. doi: 10.1038/nchembio.118 18936753
10. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, et al. (2013) Cancer genome landscapes. Science 339: 1546–1558. doi: 10.1126/science.1235122 23539594
11. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, et al. (2013) Mutational landscape and significance across 12 major cancer types. Nature 502: 333–339. doi: 10.1038/nature12634 24132290
12. Kathiresan S, Srivastava D, (2012) Genetics of human cardiovascular disease. Cell 148: 1242–1257. doi: 10.1016/j.cell.2012.03.001 22424232
13. Huynen MA, Snel B, Mering von C, Bork P, (2003) Function prediction and protein networks. Curr Opin Cell Biol 15: 191–198. 12648675
14. Szklarczyk D, Franceschini A, Kuhn M, Simonovic M, Roth A, et al. (2011) The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res 39: D561–D568. doi: 10.1093/nar/gkq973 21045058
15. Yildirim MA, Goh K-I, Cusick ME, Barabási A-L, Vidal M, (2007) Drug-target network. Nat Biotechnol 25(10): 1119–1126. 17921997
16. Campillos M, Kuhn M, Gavin A- C, Jensen LJ, Bork P, (2008) Drug target identification using side-effect similarity. Science 321: 263–266. doi: 10.1126/science.1158140 18621671
17. Hase T, Tanaka H, Suzuki Y, Nakagawa S, Kitano H, (2009) Structure of protein interaction networks and their implications on drug design. PLoS computational biology 5: e1000550. doi: 10.1371/journal.pcbi.1000550 19876376
18. Zhu M, Gao L, Li X, Liu Z, (2009) Identifying drug-target proteins based on network features. Sci China C Life Sci 52: 398–404. doi: 10.1007/s11427-009-0055-y 19381466
19. Orchard S, Orchard S, Kerrien S, Kerrien S, Abbani S, et al. (2012) Protein interaction data curation: the International Molecular Exchange (IMEx) consortium. Nat Methods 9: 345–350. doi: 10.1038/nmeth.1931 22453911
20. Sharan R, Ulitsky I, Shamir R, (2007) Network-based prediction of protein function. Mol Syst Biol 3: 1–13.
21. Ho H, Milenkovic T, Memisevic V, Aruri J, Przulj N, et al. (2010) Protein interaction network topology uncovers melanogenesis regulatory network components within functional genomics datasets. BMC systems biology 4: 84. doi: 10.1186/1752-0509-4-84 20550706
22. Janjić V, Pržulj N, (2012) The Core Diseasome. Mol Biosyst 8: 2614–2625. doi: 10.1039/c2mb25230a 22820726
23. Memisevic V, Milenkovic T, Przulj N, (2010) Complementarity of network and sequence information in homologous proteins. Journal of integrative bioinformatics 7.
24. Milenković T, Memišević V, Ganesan AK, Pržulj N, (2009) Systems-level cancer gene identification from protein interaction network topology applied to melanogenesis-related functional genomics data. Journal of The Royal Society Interface.
25. Aragues R, Sander C, Oliva B, (2008) Predicting cancer involvement of genes from heterogeneous data. BMC bioinformatics 9:172. doi: 10.1186/1471-2105-9-172 18371197
26. Li L, Zhang K, J L S C Davis DP, et al. (2009) Discovering cancer genes by integrating network and functional properties. BMC Med Genomics 2:61. doi: 10.1186/1755-8794-2-61 19765316
27. Futreal PA, Coin L, Marshall M, Down T, Hubbard T, et al. (2004) A census of human cancer genes. Nat Rev Cancer 4: 177–183. 14993899
28. Yua QHJ, (2012) The Analysis of the Druggable Families Based on Topological Features in the Protein-Protein Interaction Network. Letters in Ddrug Design & Discovery 9: 426–430.
29. Workman P, Al-Lazikani B, Clarke PA, (2013) Genome-based cancer therapeutics: targets, kinase drug resistance and future strategies for precision oncology. Curr Opin Pharmacol 13: 486–496. doi: 10.1016/j.coph.2013.06.004 23810823
30. Al-Lazikani B, Banerji U, Workman P, (2012) Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol 30: 679–692. doi: 10.1038/nbt.2284 22781697
31. Mora A, Donaldson I, (2012) Effects of protein interaction data integration, representation and reliability on the use of network properties for drug target prediction. BMC bioinformatics 13: 294. doi: 10.1186/1471-2105-13-294 23146171
32. Overington JP, Al-Lazikani B, Hopkins AL, (2006) How many drug targets are there? Nat Rev Drug Discov 5: 993–996. 17139284
33. Halling-Brown MD, Bulusu KC, Patel M, Tym JE, Al-Lazikani B, (2011) canSAR: an integrated cancer public translational research and drug discovery resource. Nucleic Acids Res 40: D947–D956. http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=22013161&retmode=ref&cmd=prlinks. doi: 10.1093/nar/gkr881 22013161
34. Bulusu KC, Tym JE, Coker EA, Schierz AC, Al-Lazikani B, (2014) canSAR: updated cancer research and drug discovery knowledgebase. Nucleic Acids Res 42: D1040–D1047. doi: 10.1093/nar/gkt1182 24304894
35. Burt RS, (1995) Structural Holes. Harvard University Press. 1 pp.
36. Freeman LC, (1977) A set of measures of centrality based on betweenness. Sociometry.
37. Voevodski K, Teng SH, Xia Y, (2009) Finding local communities in protein networks. BMC bioinformatics 10: 297. doi: 10.1186/1471-2105-10-297 19765306
38. Lewis AC, Jones NS, Porter MA, Deane CM, (2010) The function of communities in protein interaction networks at multiple scales. BMC systems biology 4: 100. doi: 10.1186/1752-0509-4-100 20649971
39. Przulj N, (2007) Biological network comparison using graphlet degree distribution. Bioinformatics 23: e177–e183. 17237089
40. Laplante M, Sabatini DM, (2009) mTOR signaling at a glance. J Cell Sci 122: 3589–3594. doi: 10.1242/jcs.051011 19812304
41. McKusick-Nathans Institute of Genetic Medicine (2012) Online Mendelian Inheritance in Man, OMIM.
42. Patel MN, Halling-Brown MD, Tym JE, Workman P, Al-Lazikani B, (2012) Objective assessment of cancer genes for drug discovery. Nat Rev Drug Discov 12: 35–50.
43. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, et al. (2012) ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res 40: D1100–D1107. doi: 10.1093/nar/gkr777 21948594
44. Bickerton GR, Higueruelo AP, Blundell TL, (2011) Comprehensive, atomic-level characterization of structurally characterized protein-protein interactions: the PICCOLO database. BMC bioinformatics 12: 313. doi: 10.1186/1471-2105-12-313 21801404
45. Chandarlapaty S, (2012) Negative feedback and adaptive resistance to the targeted therapy of cancer. Cancer Discov 2: 311–319. doi: 10.1158/2159-8290.CD-12-0018 22576208
46. Held MA, Langdon CG, Platt JT, Graham-Steed T, Liu Z, et al. (2013) Genotype-selective combination therapies for melanoma identified by high-throughput drug screening. Cancer Discov 3: 52–67. doi: 10.1158/2159-8290.CD-12-0408 23239741
47. Gowrishankar K, Snoyman S, Pupo GM, Becker TM, Kefford RF, et al. (2012) Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition. J Invest Dermatol 132: 1850–1859. doi: 10.1038/jid.2012.63 22437314
48. Al-Lazikani B, Workman P, (2013) Unpicking the combination lock for mutant BRAF and RAS melanomas. Cancer Discov 3: 14–19. doi: 10.1158/2159-8290.CD-12-0520 23319765
49. Clendening JW, Penn LZ, (2012) Targeting tumor cell metabolism with statins. Oncogene 31: 4967–4978. doi: 10.1038/onc.2012.6 22310279
50. Rual J- F, Venkatesan K, Hao T, Hirozane-Kishikawa T, Dricot A, et al. (2005) Towards a proteome-scale map of the human protein-protein interaction network. Nature 437: 1173–1178. 16189514
51. Rolland T, Taşan M, Charloteaux B, Pevzner SJ, Zhong Q, et al. (2014) A proteome-scale map of the human interactome network. Cell 159: 1212–1226. doi: 10.1016/j.cell.2014.10.050 25416956
52. Gutmanas A, Alhroub Y, Battle GM, Berrisford JM, Bochet E, et al. (2014) PDBe: Protein Data Bank in Europe. Nucleic Acids Res 42: D285–D291. doi: 10.1093/nar/gkt1180 24288376
53. Csardi G, Nepusz T, (2006) The igraph Software Package for Complex Network Research. InterJournal Complex Systems: 1695.
54. Venkatesan K, Rual J-F, Vazquez A, Stelzl U, Lemmens I, et al. (2009) An empirical framework for binary interactome mapping. Nat Methods 6: 83–90. doi: 10.1038/nmeth.1280 19060904
55. Altschul SF, Madden TL, Schäffer AA, Zhang J, Zhang Z, et al. (1997) Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 25: 3389–3402. 9254694
56. Bemis GW, Murcko MA, (1996) The properties of known drugs. 1. Molecular frameworks. J Med Chem 39: 2887–2893. 8709122
57. Potapov AP, Goemann B, Wingender E, (2008) The pairwise disconnectivity index as a new metric for the topological analysis of regulatory networks. BMC bioinformatics 9: 227. doi: 10.1186/1471-2105-9-227 18454847
58. Newman MEJ, (2004) Fast algorithm for detecting community structure in networks. Physical Review E 69: 066133.
59. Reichardt J, Bornholdt S, (2006) Statistical mechanics of community detection. Physical Review E 74: 016110.
60. Milenkovic T, Lai J, Przulj N, (2008) GraphCrunch: A Tool for Large Network Analyses, BMC Bioinformatics, 9:70. doi: 10.1186/1471-2105-9-70 18230190
61. Breiman L, (2001) Random Forests. Mach Learn 45: 5–32.
62. Ridgeway G (2006) Generalized Boosted Models: A guide to the gbm package.
63. Friedman JH, (2001) Greedy function approximation: A gradient boosting machine. Annals of Statistics 29: 1189–1232.
64. Zhang DZD, Lee WSLWS, (2008) Learning classifiers without negative examples: A reduction approach. Audio, Transactions of the IRE Professional Group on: 638–643.